Kymera Therapeutics Receives the US FDA’s Fast Track Designation to KT-333 for Cutaneous and Peripheral T-Cell Lymphoma
Shots:
- The US FDA has granted FTD to KT-333, a highly selective degrader of STAT3 for r/r CTCL & PTCL. The P-I oncology trial of KT-333 is ongoing & an update incl. an initial evaluation of its clinical antitumor activity in patients is expected in Q4’23
- The company highlighted the results from the 13 patients who received a mean of 5 doses across 1st four dose levels (DL1-4) of the trial
- Plasma exposure was found to increase across 3 dosing levels & demonstrated dose-dependent STAT3 degradation with ~88% mean maximum reduction in peripheral blood mononuclear cells and degradation profiles at DL3 that led to antitumor activity in preclinical models. KT-333 received ODD from the US FDA in 2022 for CTCL & PTCL
Ref: Globenewswire | Image: Kymera Therapeutics
Related News:- Sanofi Signs an Agreement with Kymera to Advance Novel Protein Degrader Therapies Worth Up to $2.1B
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
